Table 2.

Summary of the studies investigating the effects of cannabinoid drugs on the PPI of animal models.

Reference	Results
WIN 55, 212-2 (WIN)
Schneider and Koch, 2002	Acute administration of WIN (0.6 or 1.2 mg/kg) impairs PPI in a dose-dependent manner. The administration of haloperidol reverses the PPI deficit.
Schneider and Koch, 2003; Schneider et al., 2005	Treatment for 25 days with WIN (1.2 mg/kg) during puberty induces PPI deficits that last until adulthood. This impairment is reversed by the administration of haloperidol.
Bortolato et al., 2005	Chronic (during 7 or 21 days) or acute treatment with WIN (0.5, 1, or 2 mg/kg) does not alter PPI levels.
Wegener et al., 2008	Acute systemic administration of WIN (1.2 mg/kg), as well as the administration intra-medial prefrontal cortex or intra-dorsal hippocampus (5 μg/0.3 μl) diminish PPI levels.
Wegener and Koch, 2009	Treatment for 25 days with WIN (1.2 mg/kg) during puberty induces PPI deficits that last until adulthood. In addition, WIN treated animals display altered basal neuronal activity and respond differently to haloperidol and apomorphine.
Spano et al., 2010	Chronic WIN self-administration (12.5 μg/kg/infusion) as well as experimenter-given (0.3 mg/kg, i.v.) attenuates phencyclidine-induced impairments in PPI.
Brosda et al., 2011	Acute systemic administration of WIN (0.6 or 1.2 mg/kg) impairs PPI.
Brzózka et al., 2011	WIN (3 mg/kg) administration restores the PPI deficit induced by chronic psychosocial stress. This effect is antagonized by pretreatment with rimonabant.
Klein et al., 2013	Chronic treatment with WIN (1.2 mg/kg) during puberty induces PPI deficits that last until adulthood and are reversed by deep brain stimulation.
Levin et al., 2014	Acute administration of WIN (1 mg/kg) restores the PPI deficit displayed by the SHR strain. WIN (0.3, 1 or 3 mg/kg) does not alter the PPI of control animals.
RIMONABANT
Martin et al., 2003	Acute administration of rimonabant (5 mg/kg) does not alter PPI on its own or following disruptions by apomorphine, d-amphetamine or MK-801.
Malone et al., 2004	Rimonabant (1 or 3 mg/kg) does not alter PPI on its own. The acute administration of rimonabant (3 mg/kg) inhibits the PPI disruption promoted by apomorphine.
Malone and Taylor, 2006	Acute administration of rimonabant (5 mg/kg) is not able to counteract the PPI deficit promoted by social isolation. In addition, rimonabant does not alter the PPI of control animals.
Nagai et al., 2006	Acute administration of rimonabant (10 mg/kg) reverses the Δ9-THC-induced PPI deficit and increased dopamine release in the nucleus accumbens.
Ballmaier et al., 2007	Acute administration of rimonabant (0.75, 1.5, or 3.0 mg/kg) does not alter PPI on its own, and counteracts the PPI disruption induced by administration of phencyclidine, MK-801 or apomorphine.
Levin et al., 2014	Acute administration of rimonabant (0.75 mg/kg) worsens the PPI deficit displayed by the SHR strain. Rimonabant (0.75, 1.5, or 3 mg/kg) does not alter the PPI of control animals.
AM 404
Fernandez-Espejo and Galan-Rodriguez, 2004	AM 404 either injected acutely (2.5 mg/kg) or chronically (5 mg/kg daily, 7 days) disrupts PPI. This effect is blocked by pretreatment with rimonabant.
Bortolato et al., 2006	Acute administration of AM 404 (2.5, 5, or 10 mg/kg) does not alter PPI levels.
Levin et al., 2014	Acute administration of AM 404 (1, 5, or 10 mg/kg) does not alter the PPI of SHRs or Wistar rats.
CANNABIDIOL
Long et al., 2006	Acute administration of cannabidiol (1, 5, or 15 mg/kg) does not alter PPI on its own, but reverses (5 mg/kg) the MK-801-induced disruption of PPI. Pretreatment with capsazepine (antagonist of TRPV1 receptors) prevents cannabidiol effect.
Gururajan et al., 2011	Acute administration of cannabidiol (3, 10, or 30 mg/kg) disrupts PPI on its own, and has no effect on MK-801-induced PPI disruption.
Levin et al., 2014	Acute administration of cannabidiol (30 mg/kg) restores the PPI deficit displayed by the SHR strain. Cannabidiol administration also increases the PPI levels of control animals.
Gomes et al., 2015	Treatment with MK-801 for 28 days impairs PPI. Chronic treatment with cannabidiol (30 or 60 mg/kg) attenuates this impairment. Cannabidiol does not alter PPI on its own.
Pedrazzi et al., 2015	Pretreatment with cannabidiol (15, 30, or 60 mg/kg) attenuates the amphetamine-induced disruption of PPI. Cannabidiol does not alter PPI on its own.

MK-801, dizocilpine; PPI, prepulse inhibition of startle; SHR, spontaneously hypertensive rats; ${\Delta }_{-}^9$THC, delta-9-tetrahydrocannabinol; WIN, WIN 55212,2.